![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » UK Fines Advanz Pharma $140 Million for Inflating Thyroid Tablet Prices
UK Fines Advanz Pharma $140 Million for Inflating Thyroid Tablet Prices
August 2, 2021
The UK’s Competition and Markets Authority (CMA) has fined UK-based drugmaker Advanz Pharma and two private equity firms nearly $140 million for allegedly charging inflated prices for a drug used to treat thyroid hormone deficiency.
The CMA said Advanz supplied liothyronine tablets at “excessive and unfair prices,” with the price of thyroid tablet packs increasing from less than $28 in 2009 to nearly $345 in 2017, an increase of 1,110 percent.
The dramatic price hike led to a huge increase in costs for the National Health Service and “meant that people dealing with depression and extreme fatigue, as a result of their thyroid conditions, were told they could not continue to receive the most effective treatment for them due its increased price,” said CMA’s CEO Andrea Coscelli.
Upcoming Events
-
21Oct